Institution
Sunovion
Company•London, United Kingdom•
About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..
Topics: Lurasidone, Placebo, Population, Eszopiclone, Atypical antipsychotic
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this paper, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was successfully developed and validated for the simultaneous quantitation of ulotaront and its N-desmethyl metabolite (M11A) in human plasma.
4 citations
•
26 May 2011TL;DR: In this article, compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is R 1 and R 2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R 11 and L is C(R 6 ) 2,C(R 7 ) 2 ) 2 ), B is a hetero-aromatic group defined herein; and -A 1 -A 2 -, A 3, A 6 and R 6 are defined herein.
Abstract: Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is
R 1 and R 2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R 11 ; L is —C(R 6 ) 2 —C(R 6 ) 2 —; B is a heteroaromatic group defined herein; and -A 1 -A 2 - , A 3 , R 11 and R 6 are defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
4 citations
•
10 Jun 1999TL;DR: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia and bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its stereoisomer as discussed by the authors.
Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
4 citations
••
TL;DR: High adherence to SCBs was associated with improved HRQoL, lower WPAI, and lower HRU and associated costs among patients with epilepsy and can help provide further impetus to healthcare policymakers and clinicians for addressing the low antiepileptic drug (AED) adherence levels.
4 citations
••
09 Nov 2017TL;DR: To investigate whether adjunctive eslicarbazepine acetate (ESL) could lead to exacerbation of seizures in some patients, a large number of patients with atypical seizure histories are treated with ESL.
Abstract: Objective To investigate whether adjunctive eslicarbazepine acetate (ESL) could lead to exacerbation of seizures in some patients. Methods Post-hoc analysis of data pooled from three Phase III trials of adjunctive ESL (studies 301, 302, and 304) for refractory partial-onset seizures (POS). Following an 8-week baseline period, patients were randomized to receive placebo or ESL 400, 800, or 1,200 mg once daily (2-week titration, 12-week maintenance, 2-4 week tapering-off periods). Patient seizure diary data and seizure treatment-emergent adverse event (TEAE) reports were pooled for analysis. Results The modified intent-to-treat and safety populations comprised 1,410 patients and 1,447 patients, respectively. Titration period: Compared with placebo (32/21%), significantly smaller proportions of patients taking ESL 800 mg (20/15%) and 1,200 mg (22/12%) had a ≥25/≥50% increase in standardized seizure frequency (SSF) from baseline; there was no significant difference between placebo and ESL 400 mg. Maintenance period: Compared with placebo (20%), significantly smaller proportions of patients taking ESL (400 mg, 12%; 800 mg, 12%; 1,200 mg, 14%) had an increase in SSF ≥25%. When evaluating ≥50% increases in SSF, only ESL 800 mg (7%) was significantly different from placebo (12%). Some patients had no secondarily generalized tonic-clonic (sGTC) seizures during baseline but had ≥1 sGTC seizure during maintenance treatment (placebo, 11%; ESL 400 mg, 5%; 800 mg, 10%; 1,200 mg, 5%). Fewer patients had a ≥25% increase in sGTC seizure frequency with ESL (400 mg, 11%; 800 mg, 9%; 1,200 mg, 14%) versus placebo (19%). The incidence of seizures reported as TEAEs was low in all treatment groups; incidences were generally lower with ESL versus placebo. Tapering-off period: Similar proportions of patients taking ESL and placebo had a ≥25/≥50% increase in SSF. Seizure TEAE incidence was numerically higher with ESL versus placebo. Significance Treatment with adjunctive ESL does not appear to aggravate POS or sGTC seizures.
4 citations
Authors
Showing all 572 results
Name | H-index | Papers | Citations |
---|---|---|---|
Chris H. Senanayake | 58 | 588 | 12142 |
Paul J. Reider | 55 | 344 | 9827 |
Antony Loebel | 42 | 223 | 6906 |
Kenneth S. Koblan | 40 | 96 | 4380 |
Richard G. Ball | 37 | 142 | 3684 |
Robert D. Larsen | 36 | 147 | 3544 |
Robert Goldman | 35 | 110 | 7064 |
Raymond L. Woosley | 34 | 115 | 3811 |
Rudy Schreiber | 33 | 80 | 3793 |
Thomas R. Verhoeven | 29 | 127 | 3135 |
Andrei Pikalov | 28 | 120 | 2583 |
David Blum | 27 | 89 | 2958 |
Mark A. Varney | 26 | 41 | 4032 |
Lisa DiMichele | 25 | 88 | 1755 |
John P. Hanrahan | 25 | 46 | 2781 |